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Simple Summary: Soluble forms of checkpoint protein PD-1 and its ligand PD-L1 can be measured
from circulation, but their source, function, and clinical impact in cancer remain incompletely
understood. In this study, we used serum samples collected during a conduction of a prospective
immunochemotherapy trial in patients with high-risk diffuse large B-cell lymphoma (DLBCL) and
assessed their clinical significance. Our results demonstrate that sPD-1 levels in the peripheral blood
at the time of diagnosis correlate with the quantities of tumor infiltrating PD1+ T cells and translate
to inferior survival. To our knowledge, this is the first study to identify sPD-1 as a prognostic factor,
providing interesting perspectives on future clinical trials in DLBCL, including patients’ stratification
associated with checkpoint blockade.
Abstract: Interaction of checkpoint receptor programmed death 1 (PD-1) with its ligand 1 (PD-L1)
downregulates T cell effector functions and thereby leads to tumor immune escape. Here, we aimed
to determine the clinical significance of soluble PD-1 (sPD-1) and soluble PD-L1 (sPD-L1) in patients
with diffuse large B-cell lymphoma (DLBCL). We included 121 high-risk DLBCL patients treated
in the Nordic NLG-LBC-05 trial with dose-dense immunochemotherapy. sPD-1 and sPD-L1 levels
were measured from serum samples collected prior to treatment, after three immunochemotherapy
courses, and at the end of therapy. sPD-1 and sPD-L1 levels were the highest in pretreatment samples,
declining after three courses, and remaining low post-treatment. Pretreatment sPD-1 levels correlated
with the quantities of PD1+ T cells in tumor tissue and translated to inferior survival, while no
correlation was observed between sPD-L1 levels and outcome. The relative risk of death was 2.9-fold
(95% CI 1.12–7.75, p = 0.028) and the risk of progression was 2.8-fold (95% CI 1.16–6.56, p = 0.021)
in patients with high pretreatment sPD-1 levels compared to those with low levels. In conclusion,
pretreatment sPD-1 level is a predictor of poor outcome after dose-dense immunochemotherapy and
may be helpful in further improving molecular risk profiles in DLBCL.
Keywords: soluble PD-1; soluble PD-L1; diffuse large B-cell lymphoma; survival
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1. Introduction
Approximately two-thirds of patients with diffuse large B-cell lymphoma (DLBCL) are
cured in response to standard rituximab, cyclophosphamide, doxorubicin, vincristine, and
prednisone (R-CHOP)-based immunochemotherapy [1]. However, treatment options for
primary refractory and relapsed patients are few, and the disease is often fatal. If molecular
factors determining the poor prognosis were understood better, targeted therapies could
be applied not only to improve outcomes in these patients but also to avoid overtreatment.
DLBCL is a heterogeneous disease. Recent comprehensive genome and transcriptome
studies elucidated the heterogeneity of DLBCL and revealed multiple DLBCL subtypes
with different outcomes [2–4]. In addition to tumor-cell-derived factors, an association
between tumor microenvironment (TME) and survival was identified. Among the most
essential prognostic microenvironmental factors are tumor-infiltrating T cells (TILs) [5–7].
Antitumor T cell responses are critical for immune surveillance of malignant diseases,
but they may be counterbalanced by a number of immune checkpoints used by tumors to
actively evade immune destruction [8]. Among all immune checkpoints, the programmed
cell death 1 (PD-1; also called CD279)/programmed death ligand 1 (PD-L1; CD274) path-
way stands out because of its value as a therapeutic target in many malignancies [9,10].
PD-1 interacts with PD-L1 and PD-L2 (CD273), of which PD-L1 is considered as a dominant
inhibitory ligand of PD-1 in human TME. While PD-1 is expressed mainly on activated T
cells, PD-L1 expression is broader, including tumor cells, tumor infiltrating immune cells,
and cells in circulation, such as neutrophils [11]. Interaction of PD-L1 with PD-1 results
in downregulation of T cell effector functions and inhibition of the antitumor immune
response [10–12].
In DLBCL, roles of PD-1 and PD-L1 expression remain obscure, as, depending on
assessment method, target cells (TME or tumor cells), and used cutoff levels, some studies
found high amounts of PD-1+ TILs or PD-L1 expression to be associated with poor outcomes,
whereas other studies showed favorable or no prognostic impact on survival [12–19].
In addition to full-length, membrane-bound isoforms, alternatively spliced PD-1
and PD-L1 transcripts were described [20–22]. A splice variant PD-14ex3 lacking the
transmembrane domain results into production of soluble PD-1 (sPD-1). sPD-1 bind to
PD-L1/L2 in vitro, thereby blocking interaction between membrane-bound PD-1 (mPD-
1) and PD-L1/L2 [23]. This could lead to inhibition of negative signals provided by
mPD-1 and expose cancer cells to immune surveillance. Consistent with the hypothesis
that sPD-1 could act as a checkpoint inhibitor was the finding that coadministration of
sPD-1-encoding DNA with two different vaccines enhanced antigen-specific CD8+ T cell
responses, resulting in antitumor effects in mice [24]. Furthermore, sPD-1 expressing
senescent tumor cell vaccine delayed tumorigenesis and suppressed tumor growth in a
triple-negative breast cancer mouse model [25]. Similarly, a splice variant CD274-L2A
resulted in a membrane-free, soluble form of PD-L1 (sPD-L1) [21,22]. sPD-L1 might
also result from cleavage of membrane-bound PD-L1 (mPD-L1) [26]. Recently, it was
shown that although sPD-L1 retains PD-1 binding activity on T cells, it lacks measurable
T cell inhibitory activity. Instead, sPD-L1 can act as a PD-1 antagonist by reversing T cell
suppression mediated by mPD-L1 [27].
sPD-1 and sPD-L1 can be measured from different body fluids, including serum [28–32],
but their source, function, and clinical impact in cancer remain incompletely understood.
In patients with resected hepatocellular carcinoma, elevated sPD-1 levels were shown
to be associated with favorable outcomes [29]. High serum sPD-L1 levels were in turn
associated with poor outcomes in patients with DLBCL [19,31,33]. We previously observed
elevated pretreatment sPD-1 levels in DLBCL patients compared to healthy controls [34].
In this study, we used serum samples collected during conduction of a prospective DLBCL
trial at three different time points, allowing us to analyze sPD-1 and sPD-L1 levels during
immunochemotherapy and assess whether the levels were associated with outcome.
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2. Results
2.1. Clinical Characteristics
The Nordic Lymphoma Group Large B-Cell (NLG-LBC-)05 trial included 139 patients
aged 18–64 years, who had primary DLBCL with age-adjusted International Prognostic In-
dex (aaIPI) 2–3 or site-specific risk factors for central nervous system (CNS) recurrence [35].
The patients were treated with dose-dense immunochemotherapy and systemic early CNS
prophylaxis [35]. Patient demographics of the study cohort (n = 121) were representative of
the entire clinical trial (Table 1). Most of the patients had DLBCL not otherwise specified
(NOS, n = 105, 87%), eight (7%) patients had primary mediastinal B-cell lymphoma, three
(2%) had grade IIIb follicular lymphoma, four (3%) had T cell/histiocyte-rich large B-cell
lymphoma, and one (1%) had intravascular large B-cell lymphoma. No EBV+ DLBCL NOS
cases were included. The median age was 56 years (range 21–65 years). The majority of
the patients were males with good Eastern Cooperative Oncology Group (ECOG) perfor-
mance scores and advanced stage disease. In addition, 74 (61%) patients had B symptoms
and 110 (91%) had elevated lactate dehydrogenase (LDH). During the median follow up
time of 61 months (range 40–85 months), 18 (15%) patients relapsed and 16 (13%) died,
translating to 87% OS and 83% PFS rates at five years. Twelve (10%) of the deaths were
lymphoma-related.
Table 1. Characteristics of all patients in the study and according to pretreatment sPD-1 and sPD-L1 levels.



















Total 121 (100) 80 (66) 41 (34) 40 (50) 40 (50)
Median age
(range) 56 (21–65) 54 (21–65) 57 (30–65) 54 (21–65) 54 (22–65)
Age
<60 years 82 (68) 54 (68) 28 (68) 1.000 30 (75) 29 (73) 0.799
60–65 years 39 (32) 26 (32) 13 (32) 10 (25) 11 (27)
Gender
Male 75 (62) 46 (58) 29 (71) 0.172 25 (63) 26 (65) 0.816
Female 46 (38) 34 (42) 12 (29) 15 (37) 14 (35)
Entity
DLBCL NOS
GCB 53 (44) 41 (51) 12 (29) 0.055 1 18 (45) 17 (42) 0.788 1
Non-GCB 36 (30) 21 (26) 15 (37) 11 (28) 12 (30)
ND 16 (13) 10 (13) 6 (15) 2 (5) 5 (13)
Other 16 (13) 8 (10) 8 (19) 9 (22) 6 (15)
ECOG PS
0–1 86 (71) 60 (75) 26 (63) 0.208 32 (80) 20 (50) 0.005
2–3 35 (29) 20 (25) 15 (37) 8 (20) 20 (50)
Stage
1–2 8 (7) 8 (10) 0 (0) 0.050 5 (13) 1 (3) 0.090
3–4 113 (93) 72 (90) 41 (100) 35 (87) 39 (98)
aaIPI score
0 4 (3) 4 (5) 0 (0) 0.341 4 (10) 0 (0) 0.016
1 6 (5) 4 (5) 2 (5) 2 (5) 2 (5)
2 74 (61) 51 (64) 23 (56) 25 (63) 18 (45)
3 37 (31) 21 (26) 16 (39) 9 (22) 20 (50)
1 Comparing GCB and non-GCB. NOS, not otherwise specified; GCB, germinal center B-cell-like; non-GCB, nongerminal center B-cell-like;
ND, not determined; ECOG PS, Eastern Cooperative Oncology Group performance status; aaIPI, age-adjusted International Prognostic
Index. The differences in the frequency of prognostic factors in the patient subgroups were compared with chi-square test and the
Fisher–Freeman–Halton tests. Statistically significant p-values are bolded.
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2.2. sPD-1 and sPD-L1 Levels During Therapy
sPD-1 and sPD-L1 levels were measured at three different time points. The highest
sPD-1 levels were observed pretherapeutically (median 973 pg/mL, range 40 pg/mL to
10,761 pg/mL). A significant decline in sPD-1 levels compared to pretherapeutic levels
was observed in response to immunochemotherapy after three treatment courses (median
81 pg/mL, range 40–1163 pg/mL, p < 0.001) and after all courses (median 185 pg/mL, range
40–1525 pg/mL, p < 0.001; Figure 1A). Post-treatment levels were higher than levels during
therapy (p < 0.001; Figure 1A). Similarly, sPD-L1 levels were highest pretherapeutically
(median 766 pg/mL, range 56–5393 pg/mL), declining during therapy (median 244 pg/mL,
range 56–3905 pg/mL, p < 0.001), and remaining significantly lower after all courses
(median 402 pg/mL, range 56–3712 pg/mL; Figure 1B) compared to pretreatment levels
(p < 0.001). No correlation was seen between sPD1 and sPD-L1 levels (in all comparisons,
p > 0.43).
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Figure 1. sPD-1 and sPD-L1 levels during different time points. Pretreatment, after three treatment
courses, and post-treatment levels of (A) soluble PD-1 and (B) soluble PD-L1 and the significance of
the level change between these three time points *.
2.3. Correlation of sPD-1 and sPD-L1 Levels with Clinical Parameters, Gene and Protein
Expression and Lymphocyte Count
Patients with advanced stage (III-IV), elevated LDH, and high aaIPI (2–3) score had
higher pretreatment sPD-1 levels compared to patients with low stage (I-II), normal LDH,
and low aaIPI (0–1), respectively (Figure 2A). In addition, sPD-1 levels tended to be higher
in patients who had high PD1+ T cell contents in their tumor tissue (>median, Figure 2A),
whereas no differences were observed in pretreatment sPD-1 levels between good and poor
performance scores (0–2 vs. 3–4), gender, age (<60 years vs. 60–6 years), or molecular
subtype. In comparison, pretreatment sPD-L1 levels analyzed as continuous variables
(Mann-Whitney U test, p = 0.002) were higher in patients with poor ECOG PS, whereas no
correlation was seen between other clinical parameters or PD-L1+ TAM count and sPD-L1
levels (Figure 2B).
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sPD-1 levels and clinical stage, lactate dehydrogenase (LDH) level, age-adjusted International Prognostic Index (aaIPI) score,
and PD-1+ tumor infiltrating T lymphocytes (TILs). (B) Correlation between pretreatment sPD-L1 levels and clinical stage,
LDH leve , aaIPI score, and PD-L1+ tumor-associated macrophages (TAMs). sPD-1 and sPD-L1 values were analyzed as
continuous variables and the levels between the groups were compared with the Mann–Whitney U test.
Pretreatment sPD-1 level correlated with PDCD1 gene expression in matching tumor
tissue (ρ = 0.467, p < 0.001; Figure 3A). In addition, we found a positive correlation between
pretreatment sPD-1 levels and quantities of tumor infiltrating PD-1+ T cells (ρ = 0.396,
p = 0.012, n = 39; Figure 3B), PD-1+ T-helper cells (ρ = 0.433, p = 0.019, n = 29), PD-1+
cytotoxic T cells (ρ = 0.385, p .039, n = 29), and PD-L1+ tumor-associated macrophages
(TAMs) (ρ = 0.397, p = 0.012, n = 39). In contrast, no correlation was found between
pretreatment sPD-1 levels and PD-1+ TAMs (p = 0.6, n = 39), nor blood absolute lymphocyte
counts (p = 0.6, n = 102). Neither did we observe any correlation between sPD-L1 levels
and PD-L1 gene-expression level (p = 0.80) or tumor infiltrating PD-L1+ cells (p = 0.92) or
PD-L1+ TAMs (p = 0.57).
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2.4. Association of sPD-1 and sPD-L1 Levels with Survival
According to a receiver operating characteristics (ROC) analysis, a pretreatment sPD-1
cutoff level of 1565 pg/mL, corresponding to 66%, best separated the two subgroups with
different outcomes. Patients with high pretreatment sPD-1 levels (highest third, “high
sPD-1 group”) had significantly worse outcomes than patients with low pretreatment
sPD-1 levels (lowest two-thirds, “low sPD-1 group”) (five-year OS 78% vs. 91%, p = 0.021;
five-year PFS 73% vs. 89%, p = 0.016; Figure 4).
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In the high sPD-1 group, relative risk of death was increased 2.9-fold (95% CI 1.12–7.75,
p = 0.028) and risk of progression by 2.8-fold (95% CI 1.16–6.56, p = 0.021), compared to the
low sPD-1 group. Patients in the high sPD-1 group more often demonstrated advanced
stage compared to the low sPD-1 group (p = 0.050). However, the prognostic impact
of sPD-1 levels on OS (HR 2.64, 95% CI 1.01–6.94, p = 0.049) and PFS (HR 2.47, 95% CI
1.04–5.86, p = 0.040) was sustained when adjusted for stage. Other baseline characteristics
were equally distributed between sPD-1 high and low subgroups (Table 1). In multivariate
analysis with age, ECOG performance score, stage, LDH level, and molecular subtype,
pretreatment sPD-1 level was retained as the only prognostic factor for OS and PFS (Table 2).
In comparison, pretreatment sPD-L1 levels were not associated with survival in this cohort
(Figure 4B). The patients with high pretreatment sPD-L1 levels (>median) had worse ECOG
performance scores more often (PS 2–3: p = 0.005) and higher aaIPI scores (p = 0.016) than
the patients with low pretreatment sPD-L1 levels. Otherwise, baseline characteristics
were equally distributed between sPD-L1 high and low subgroups (Table 1). Neither the
levels of sPD-1 nor sPD-L1 levels measured after three treatment courses or post-treatment
translated to poor outcome.
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Table 2. Multivariate Cox regression analysis.
Variable
OS PFS
HR 95% CI p Value HR 95% CI p Value
sPD-1, low vs. high 4.06 1.00–16.50 0.050 4.10 1.21–13.89 0.024
Age 1.03 0.95–1.12 0.446 1.06 0.98–1.14 0.165
ECOG PS (0, 1, 2, 3) 1.59 0.77–3.25 0.209 1.30 0.70–2.40 0.403
Stage (1, 2, 3, 4) 0.81 0.27–2.40 0.700 1.02 0.35–2.93 0.975
LDH, low vs. high 1.27 0.14–11.51 0.830 0.99 0.12–8.43 0.995
Subtype, GCB vs.
non-GCB 1.27 0.37–4.34 0.706 1.07 0.36–3.17 0.899
OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; sPD-1, soluble
programmed cell death 1; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate
dehydrogenase; GCB, germinal center B-cell-like; non-GCB, nongerminal center B-cell-like. Statistically significant
p-values are bolded. sPD-1 level, LDH value and molecular subtype were analyzed as categorized variables and
the others as continuous variables.
3. Discussion
Although the role of mPD-1 as a key immune-checkpoint protein expressed on ac-
tivated T cells is well established, and the PD-14ex3 splice variant encoding sPD-1 was
originally described 15 years ago [20], the function and clinical impact of sPD-1 remain
unclear. Particularly in hematologic malignancies, data on sPD-1 are limited. Further-
more, while there are data showing correlation of sPD-L1 with outcome in patients with
DLBCL [31], the clinical impact of sPD-L1 in the high-risk subgroup in combination with
sPD-1 was not previously addressed. As the clinical course of the patients with DLBCL
is heterogeneous, even within different International Prognostic Index risk groups, novel,
easily measurable molecular tools for risk stratification would be needed. Measuring solu-
ble biomarkers at diagnosis or during the course of therapy is practical, as blood samples
can be collected easily from all patients.
This study was established along with a prospective clinical trial exploring whether
dose-dense immunochemotherapy and early CNS prophylaxis improves outcomes and
reduces the incidence of CNS events in patients with high-risk DLBCL [35]. We determined
sPD-1 and sPD-L1 levels in serum samples before, during, and after therapy, and correlated
the findings with baseline characteristics and survival. We observed that the levels of
both sPD-1 and sPD-L1 were highest pretherapeutically, declining significantly in response
to immunochemotherapy, and remaining low after therapy. The pretreatment sPD-1
levels were similar to the levels we detected previously in another DLBCL cohort [34].
The findings were also consistent with a small study on classical Hodgkin lymphoma,
demonstrating a significant reduction in sPD-1 levels in response to therapy [30]. The
reason for the decline in sPD-1 and sPD-L1 levels during the course of therapy is unknown;
nevertheless, we speculate that it is due to the cytoreductive and immunosuppressive
effect of the dose-dense treatment on T cells and other hematologic cell types, particularly
neutrophils [21].
Opposite to our previous finding that PD-1 expression in the tumor tissue does not
translate to adverse outcome [15], we observed that pretreatment sPD-1 levels correlated
with more aggressive disease and unfavorable outcomes in our selected, clinically high-risk
patient population. Nevertheless, high pretreatment sPD-1 level was the only prognostic
factor for OS and PFS. Considering the correlation between pretreatment sPD-1 levels
and quantity of tumor infiltrating PD-1+ T cells in our cohort, we speculate that increased
sPD-1 levels can indicate systemic inflammation provoked by inflammatory tumor cells.
In addition, it is possible that sPD-1 is derived at least partially from tumor-infiltrating
T cells. However, the phenotype of these T cells remains to be characterized. It is also
plausible that pretreatment sPD-1 levels mirror T cell exhaustion, thereby connecting to the
detrimental clinical course of the disease. In contrast, we did not observe any correlation
between sPD-L1 levels and tumor-derived PD-L1 expression, implying that sPD-L1 is
not a simple surrogate of PD-L1 expression by the tumor tissue. Similar to our findings,
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Keane et al. observed no correlation between sPD-L1 and PDL1+ T cells in the tumor
tissue [36]. In addition, apart from the patients with high sPD-L1 levels showing poor
performance scores (ECOG 2–3) more often than the patients with low sPD-L1 levels, we
could not find any association of sPD-L1 levels with clinical characteristics or outcome.
This observation differs from a study where sPD-L1 levels were shown to correlate with
unfavorable outcome in response to R-CHOP [31]. Our data are, however, similar to the
finding from the validation cohort of the same study, where the patients were treated
uniformly with high-dose chemotherapy supported with autologous transplantation [31].
These results indicate a possible attenuation of the high sPD-L1 effect on the prognosis by
the high-dose intensity treatment.
Our results were opposite to the initial hypothesis based on the potential of sPD-1 to
act as a checkpoint-inhibitor-like protein by binding to mPD-L1 and mPD-L2. Supporting
our finding, natural sPD-1 was shown to have a low binding affinity to mPD-L1 and
mPD-L2 [37], and therefore high-affinity PD-1 molecules were developed [38]. Thus, it
seems likely that although sPD-1 levels are high prior to treatment, they do not translate to
a similar outcome as checkpoint inhibitors due to weak sPD-1 binding affinity. Considering
that PD-L1 is expressed on TAMs, apart from binding to PD-L1 on tumor cells, sPD-1
might also bind to PD-L1 on TAMs. Along with our observations, responses to a PD-1
antibody, nivolumab, were shown to be low in a recent phase II trial for the patients with
relapsed/refractory DLBCL [39]. Conversely, PD-L1 gene alterations were associated with
better response to pembrolizumab [17]. Thus, it was suggested that low PD-L1 expression
on lymphoma cells would explain, at least to some extent, why the majority of the DLBCL
patients do not benefit from checkpoint blockade [17,39,40]. This may also explain why
sPD-1 does not have significant antitumor activity in DLBCL. Given that sPD-L1 can be
detected in peripheral blood, it is also possible that the interaction between sPD-1 and
sPD-L1 blocks the interaction between sPD-1 and mPD-L1. Taken together, it seems likely
that, apart from predicting outcome, sPD-1 and sPD-L1 and possibly their ratio represent
another unanticipated element contributing to final immune response.
Our study demonstrates that high sPD-1 levels in peripheral blood at the time of
diagnosis are associated with poor survival in patients diagnosed with clinically high-risk
DLBCL treated uniformly in a multicenter clinical trial. Our findings should be confirmed
in a large independent cohort. Nevertheless, to our knowledge, this is the first study to
identify sPD-1 as a prognostic factor, providing interesting perspectives on future clinical
trials in DLBCL, including patients’ stratification associated with checkpoint blockade.
4. Materials and Methods
4.1. Patients
The study population consisted of 121 young, high-risk patients with primary DLBCL
from a Nordic multicenter phase II NLG-LBC-05 trial [35] selected based on the availability
of serum samples. The patients were treated with biweekly rituximab, cyclophosphamide,
doxorubicin, etoposide, and prednisone (R-CHOEP) immunochemotherapy and systemic
early central nervous system (CNS) prophylaxis (high-dose (HD) methotrexate (Mtx) and
HD-cytarabine) [35]. Pretreatment serum samples for sPD-1 measurement were available
from all patients (n = 121), after three treatment courses from 95 patients and after all
courses from 98 patients, and for sPD-L1 measurement from 80 patients at all three time
points. All patients signed informed consent before study participation. The Institutional
Review Boards, National Medical Agencies, and Ethics Committees in Finland, Norway,
Denmark, and Sweden approved the protocol and sampling. The trial was registered at
www.ClinicalTrials.gov, number NCT01325194.
4.2. Measurement of sPD-1 and sPD-L1 Levels
sPD-1 levels were measured from the serum samples using a self-established Time-
Resolved Immunofluorometric Assay (TRIFMA) based on commercial antibodies. Wells
of 96-well plates were coated with antihuman PD-1 antibodies (1 µg/mL) in phosphate-
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buffered saline (PBS) (pH 7.4), and residual binding sites were blocked for 1 h with PBS,
1% Tween20 (Tw). Recombinant PD-1 in the range from 39 to 2500 pg/mL was used as
a standard (Bio-Techne #DY1086, R&D Systems, Abingdon, UK). Serum samples were
diluted 4-fold in the assay buffer (PBS with 5% skim milk, 1% bovine serum albumin, 2%
normal goat serum and 0.05% Tw). Bound PD-1 was determined by incubation with biotin-
labeled antihuman PD-1 antibody (200 ng/mL) in the assay buffer, followed by addition
of 10 ng Eu3+-labeled streptavidin (Perkin Elmer Life Sciences, Turku, Finland). Bound
europium was detected by the addition of 200 µL of enhancement solution (Perkin Elmer
Life Sciences, Turku, Finland) and reading the time-resolved fluorescence on a DELFIA
fluorometer (Victor, Perkin Elmer, MA, USA). All samples were analyzed in duplicate. The
detection limit was 40 pg/mL, as previously reported, and samples below this cutoff were
assigned this value [41]. Wells receiving buffer only were used as negative controls. The
intra-assay variations (%CV) were 5.2%. A normal serum sample and a spiked serum
sample were used as internal controls, with inter-assay CV of 21% and 9%, respectively. No
freeze/thaw interference was observed, and addition of PD-L1 or human serum albumin
did not influence the results.
Soluble PD-L1 was measured using an enzyme-linked immunosorbent assay (ELISA)
(PDCD1LG1, Cloud-Clone Corp., Houston, TX, USA) according to the manufacturer’s
instructions. The detection range was 0.156–10 ng/mL and the minimum detectable dose
was 0.056 ng/mL; samples below this cutoff were assigned this value. All samples were
diluted 1:3 in PBS and analyzed in duplicate. A normal serum sample and a spike serum
sample were used as internal controls.
4.3. PD-1 and PD-L1 Gene Expression in the Tumor Tissue, Multiplex Immunohistochemistry, and
Blood Lymphocyte Counts
PD-1 and PD-L1 encoding mRNA levels were measured from tumor samples using
digital gene expression analysis with NanoString nCounter (Nanostring Technologies,
Seattle, WA, USA), as described previously [15]. Proportions of PD-1-, PD-L1-, CD3-,
CD4-, CD8-, and CD68-positive cells in tumor tissues analyzed by multiplex immunohis-
tochemistry staining were described previously [15,42]. Blood lymphocyte values were
obtained from routine automated complete blood count determination from peripheral
blood samples collected prior to treatment initiation.
4.4. Statistical Analyses
Statistical analyses were performed with IBM SPSS Statistics v.25.0 (IBM, Armonk,
NY, USA). The significance of difference in sPD-1 and sPD-L1 levels between time points
was evaluated with Wilcoxon signed ranks test. The difference in sPD-1 and sPD-L1 levels
between groups was evaluated using the Mann–Whitney U test. Correlation analyses were
performed with Spearman rank analysis. ROC curve analysis was used to determine the
optimal cutoff-point for the pretreatment sPD-1 level. In the ROC curve analysis, survival
outcomes were dichotomized into progression-free survival (PFS) events (relapse or death
versus no relapse or death). The Kaplan–Meier method was used to estimate the survival
rates and the log-rank test was used to compare the differences between the groups. The
prognostic impact was estimated by Cox univariate regression analysis (95% confidence
interval) with categorized values. The chi-square test and the Fisher–Freeman–Halton
test were used to evaluate the differences in the frequency of prognostic factors in the
patient groups. Overall survival (OS) was defined from the date of trial entry until the last
follow-up or death, and PFS from the date of trial entry until relapse or death. Both OS and
PFS were reported in months. p-values below 0.05 were considered statistically significant
and all statistical tests were two-tailed.
5. Conclusions
Earlier studies showed that pretreatment sPD-L1 levels correlate with poor outcome in
DLBCL patients treated with R-CHOP immunochemotherapy. However, adverse prognos-
tic impact of sPD-L1 levels was not observed in patients treated with high-dose chemother-
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apy and autologous stem cell transplantation [31]. In this study, we demonstrated that
sPD-L1 and sPD1 levels decreased in response to dose-dense immunochemotherapy in
patients with high-risk DLBCL. Furthermore, high pretreatment sPD-1 levels correlated
with the quantities of tumor-infiltrating PD1+ T cells, translating to poor survival, whereas
no correlation was observed between sPD-L1 levels and outcome. The findings provide
interesting prospects for future clinical trials in DLBCL.
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